PRMT6 and Huntington disease: Importantly, polyQ expanded mHTT does not impair the methylation of mHTT and the mHTT–PRMT6 complex formation in vivo, suggesting that PRMT6 targeting could be a possibly effective therapeutic approach for HD [36].